Hematology/Oncology

Top Story

Rivaroxaban noninferior to fondaparinux for superficial vein thrombosis

February 23, 2017

A 45-day course of rivaroxaban for the treatment of high-risk patients with superficial vein thrombosis did not increase the risk for serious complications or major bleeding events compared with fondaparinux over the same timeframe, according to findings from the SURPRISE trial presented at the ASH Annual Meeting and Exposition.

Fondaparinux (Arixtra, GlaxoSmithKline) – an indirect Factor Xa inhibitor – has been the standard of therapy for the treatment superficial vein thrombosis.

In the Journals

Oral contraceptives reduce risk for some cancers

February 23, 2017
The benefits of oral contraceptives outweigh the harms, protecting against lifetime risks of certain cancers, including endometrial, ovarian and colorectal cancer…

Palliative Care Leadership Centers expand into community setting

February 23, 2017
The Center to Advance Palliative Care announced the launch of three new Palliative Care Leadership Centers that will focus on home- and office-based care. The effort is…
In the Journals

BMJ: Trump’s policies risk ‘head-on collision’ with science, health care

February 23, 2017
A commentary recently published in The BMJ expressed the editors’ concerns with President Donald J. Trump’s policies, stating that the new…

CMS awards $100 million to support small practices in Quality Payment Program

February 23, 2017
The CMS is working with 11 local, experienced, community based organizations to provide immediate hands-on training and educational resources about the Quality Payment…
More News Headlines »
CME

Immune Checkpoint Inhibition for Melanoma Management: When, What, How, and in Whom?

This activity is supported by educational grants from Bristol-Myers Squibb and Merck & Co., Inc.

It is estimated that 76,380 new cases of melanoma will be diagnosed in the United Stated in 2017, with approximately…
More »
Video
Meeting News

VIDEO: Advances in CAR T cells offer significant potential for patients with leukemia

January 19, 2017
More »
Featured
CME

Hot Topics in Metastatic Breast Cancer Management: Clinical Advances with CDK4/6 Inhibitors

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

While the mortality rates for advanced or metastatic breast cancer (MBC) have steadily decreased, in part due to…
More »
Current Issues
View the Current Issue
HemOnc Today
Advertisement
Advertisement